OMS1029 / Omeros, University of Leicester, Helion Biotech - LARVOL DELTA

Omeros Corporation Reports First Quarter 2024 Financial Results (Businesswire) - "Our Phase 1 multiple-ascending-dose study of OMS1029 is expected to read out data later this quarter....Several large market indications are being evaluated for Phase 2 clinical development of OMS1029 and we expect to select an indication in the third quarter of 2024. The indications under consideration include neovascular age-related macular degeneration, sometimes referred to as 'wet AMD.'...'Through the sale of a portion of our OMIDRIA royalties in February, we have extended our cash runway into 2026....Omeros continues to retain any and all royalties on ex-U.S. OMIDRIA sales and, from and after January 1, 2032, all royalties globally....For the first quarter of 2024, we earned OMIDRIA royalties of $9.4 million on Rayner’s U.S. net sales of $31.2 million. This compares to earned OMIDRIA royalties of $9.2 million during the first quarter of 2023 on U.S. net sales of $30.7 million.'"

Commercial • New P2 trial • P1 data • Pain • Rare Diseases • Wet Age-related Macular Degeneration